Perhaps in the progression of CHB disease, HBV reduces the risk of atherosclerosis through the incompletely verified molecular mechanism, resulting in a negative correlation between ApoB/ApoA1 ratio and the prevalence of HCC and LC. This evidence concerns the gene APOA1 and laryngotracheoesophageal cleft.